LAVI logo

Lavipharm S.A. Stock Price

ATSE:LAVI Community·€262.7m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

LAVI Share Price Performance

€1.55
0.77 (98.47%)
€1.55
0.77 (98.47%)
Price €1.55

LAVI Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with questionable track record.

2 Risks
0 Rewards

Lavipharm S.A. Key Details

€62.6m

Revenue

€32.3m

Cost of Revenue

€30.3m

Gross Profit

€25.3m

Other Expenses

€5.0m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 28, 2026
0.03
48.42%
8.06%
36.8%
View Full Analysis

About LAVI

Founded
1911
Employees
285
CEO
Telemaque Lavidas
WebsiteView website
lavipharm.com

Lavipharm S.A. engages in the research, development, manufacture, import, marketing, sale, and wholesale of pharmaceutical, cosmetics, and healthcare products to physicians and pharmacists in Greece and internationally. The company offers pharmaceutical products for cardiology, oncology-urology, central nervous system, chronic pain, and self- treatment. It also provides prescription medicines and over the counter (OTC) products, as well as LIFELAB CBD products. The company was founded in 1911 and is based in Paiania, Greece.

Recent LAVI News & Updates

Analysis Article May 01

Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) Shareholders

Lavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...

Recent updates

No updates

Lavipharm S.A. Competitors